DMKPQ — DMK Pharmaceuticals Share Price
0.000.00%
Last trade - 00:00HealthcareHighly SpeculativeMicro Cap
- $0.00m
- -$6.66m
- $4.76m
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | n/a | ||
| Price to Tang. Book | n/a | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 0 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | n/a | ||
| Return on Equity | n/a | ||
| Operating Margin | -685.86% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 15.09 | 22.11 | 2.78 | 2.21 | 4.76 | 1.47 | 4.64 | -18.31% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
DMK Pharmaceuticals Corporation is a commercial stage neuro-biotech company. The Company is focused on developing and commercializing products for the treatment of opioid overdose and substance-use disorders. Its ZIMHI (naloxone) is FDA approved for the treatment of opioid overdose. It is focused on developing novel therapies for opioid use disorder (OUD) and other important neuro-based conditions where patients are currently underserved. Its technologies are at the forefront of endorphin-inspired drug design with its mono, bi-, and tri-functional small molecules that simultaneously modulate critical networks in the nervous system. It has a library of approximately 750 small molecule neuropeptide analogues and a differentiated pipeline. The Company’s lead clinical-stage product candidate, DPI-125, is being studied as a treatment for OUD. Its other development stage product candidates include DPI-221 for bladder control problems and DPI-289 for severe end stage Parkinson’s disease.
Directors
- Richard Williams NEC (77)
- Dennis Carlo CEO (77)
- David Benedicto CFO (60)
- David Marguglio SVP (50)
- Ronald Moss OTH (61)
- Meera Desai DRC
- Howard Birndorf IND (71)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- April 22nd, 2004
- Public Since
- August 14th, 1995
- No. of Shareholders
- 82
- No. of Employees
- 11
- Sector
- Pharmaceuticals
- Industry
- Healthcare
- Exchange
- Pink Sheets on Nasdaq
- Shares in Issue
- 10,102,050
- Address
- 11682 El Camino Real, Suite 300, SAN DIEGO, 92130
- Web
- https://www.dmkpharmaceuticals.com/
- Phone
- +1 8589972400
- Auditors
- BDO USA, LLP
Upcoming Events for DMKPQ
Q2 2024 DMK Pharmaceuticals Corp Earnings Release
Q3 2024 DMK Pharmaceuticals Corp Earnings Release
Similar to DMKPQ
Acusphere
Pink Sheets on Nasdaq
Adorbs
Pink Sheets on Nasdaq
Agentix
Pink Sheets on Nasdaq
Agrios Global Holdings
Pink Sheets on Nasdaq
Aida Pharmaceuticals
Pink Sheets on Nasdaq
FAQ
What is the DMK Pharmaceuticals share price?
As of Today at 20:16 UTC, shares in DMK Pharmaceuticals are trading at $0.00. This share price information is delayed by 15 minutes.
How has the DMK Pharmaceuticals share price performed this year?
Shares in DMK Pharmaceuticals last closed at $0.00 and the price had moved by -100% over the past 365 days. In terms of relative price strength the DMK Pharmaceuticals share price has underperformed the S&P500 Index by -100% over the past year.
What are the analyst and broker recommendations for DMK Pharmaceuticals?
The overall consensus recommendation for DMK Pharmaceuticals is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Find out moreWhat is the DMK Pharmaceuticals dividend yield?
DMK Pharmaceuticals does not currently pay a dividend.
Does DMK Pharmaceuticals pay a dividend?
DMK Pharmaceuticals does not currently pay a dividend.
When does DMK Pharmaceuticals next pay dividends?
DMK Pharmaceuticals does not currently pay a dividend.
How do I buy DMK Pharmaceuticals shares?
To buy shares in DMK Pharmaceuticals you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of DMK Pharmaceuticals?
As of the previous close price of $0.00, shares in DMK Pharmaceuticals had a market capitalisation of $0.00m.
Where are DMK Pharmaceuticals shares listed?
Here are the trading details for DMK Pharmaceuticals:
- Country of listing: United States
- Exchange: PNK
- Ticker Symbol: DMKPQ
What kind of share is DMK Pharmaceuticals?
Based on an overall assessment of its quality, value and momentum DMK Pharmaceuticals is currently classified as a . The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a DMK Pharmaceuticals share price forecast for 2025?
The analyst consensus target price for shares in DMK Pharmaceuticals is $1.50. That is 149999900% above the last closing price of $0.00.
Analysts covering DMK Pharmaceuticals currently have a consensus Earnings Per Share (EPS) forecast of -$4.39 for the next financial year.
Find out moreWhat is the trend in the DMK Pharmaceuticals share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like DMK Pharmaceuticals. Over the past six months, its share price has outperformed the S&P500 Index by +3.51%.
As of the last closing price of $0.00, shares in DMK Pharmaceuticals were trading -100% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the DMK Pharmaceuticals PE Ratio?
The DMK Pharmaceuticals PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $0.00.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of DMK Pharmaceuticals?
DMK Pharmaceuticals' management team is headed by:
- Richard Williams - NEC
- Dennis Carlo - CEO
- David Benedicto - CFO
- David Marguglio - SVP
- Ronald Moss - OTH
- Meera Desai - DRC
- Howard Birndorf - IND